K

KDL Biotech

KOPDRUGS

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

1
  • Company has low interest coverage ratio.

Growth Rate

Revenue Growth
-100% lower than 3Y
Net Income Growth
12% higher than 3Y

Quarterly Results

Particulars Mar 2013Jun 2013Sep 2013Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014
Sales
5.12
0.99
0
0
0
0
0
0
Expenses
5.41
2.23
0.7
0.44
1.17
0.31
0.3
0.34
Operating Profit
-0.29
-1.24
-0.7
-0.44
-1.17
-0.31
-0.3
-0.34
OPM %
-5.66%
-125.25%
—
—
—
—
—
—
Other Income
0.12
0.07
0.06
0.1
0.13
0.04
0.04
0.02
Interest
1.72
1.71
1.73
1.73
1.69
1.22
1.23
1.27
Depreciation
1.72
1.72
1.74
1.74
1.7
1.72
1.74
1.74
PBT
-3.61
-4.6
-4.11
-3.81
-4.43
-3.21
-3.23
-3.33
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
-3.61
-4.6
-4.11
-3.81
-4.43
-3.21
-3.23
-3.33
EPS in Rs
-1.5
-1.91
-1.71
-1.59
-1.84
-1.34
-1.34
-1.39
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2006 6mSep 2007 18mSep 2008Mar 2010 18mMar 2011Mar 2012TTM
Sales
55
165
57
38
28
26
0
Expenses
59
198
66
55
45
29
2
Operating Profit
-3
-33
-9
-17
-16
-2
-2
OPM %
-6%
-20%
-17%
-44%
-58%
-8%
—
Other Income
1
42
6
15
-11
1
0
Interest
5
13
10
3
7
7
5
Depreciation
4
10
7
12
22
9
7
PBT
-11
-13
-21
-17
-57
-17
-14
Tax %
0%
0%
0%
0%
14%
0%
—
Net Profit
-11
-14
-21
-17
-64
-17
-14
EPS in Rs
—
—
-8.79
-7.08
-26.76
-7.16
-5.91
Div. Payout %
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2006Sep 2007Sep 2008Mar 2010Mar 2011Mar 2012
Equity Capital
17
17
24
24
24
24
Reserves
-9
-9
15
-2
-66
-83
Borrowings
106
85
64
57
60
60
Other Liabilities
33
62
16
26
47
56
Total Liabilities
147
154
119
106
65
57
Fixed Assets
83
75
77
75
57
48
CWIP
0
0
6
4
0
0
Investments
0
0
0
0
0
0
Other Assets
64
79
36
27
8
9
Total Assets
147
154
119
106
65
57
Figures in ₹ Crores

Cash Flow

Particulars Mar 2006Sep 2007Sep 2008Mar 2010Mar 2011Mar 2012
Operating
-1
3
-6
3
2
7
Investing
0
-2
-15
-1
0
0
Financing
-1
-2
22
-3
-2
-7
Net Cash Flow
-2
-1
1
-1
0
0
Free Cash Flow
-1
1
-21
2
1
7
CFO/OP
15
-8
66
-19
-12
-350
Figures in ₹ Crores

Ratios

Particulars Mar 2006Sep 2007Sep 2008Mar 2010Mar 2011Mar 2012
Debtor Days
210
50
7
1
4
0
Inventory Days
118
72
55
75
126
195
Days Payable
234
129
114
469
249
426
Cash Conversion Cycle
93
-7
-53
-393
-119
-230
Working Capital Days
146
21
75
-75
-497
-643
ROCE %
—
-18%
-11%
-23%
-78%
-108%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view KDL Biotech insights

48 extracted metrics + investor summaries across FY06–FY12.

Log in — free

Documents

Frequently Asked Questions about KDL Biotech

What does KDL Biotech Ltd do?
KDL Biotech Limited manufactures biotechnology based products. The Group specializes in Semi-synthetic Penicillins and related Enzymes.
Which sector does KDL Biotech Ltd belong to?
KDL Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.

Company Information

KDL Biotech Limited manufactures biotechnology based products. The Group specializes in Semi-synthetic Penicillins and related Enzymes.

Website kdlbiotech.com
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KOPDRUGS.md for KDL Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List